Bozeman Deaconess Hospital

Below are some of the SCCA clinical trials now being offered for patients at Bozeman Deaconess Hospital. If you have any questions about these or other trials, please contact Bozeman Deaconess Hospital.

Breast Cancer (Newly Diagnosed)

• Pfizer Sutent (6488)
  A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer

• Triple Negative Gen (6628                                                                                             Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Breast Cancer (Recurrent/Metastatic)

• Triple Negative Gen (6628)
  Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Gastric, Gastroesophageal and Esophageal Cancer (Metastatic or Locally Advanced)

• Ramucirumab for Gastric, Esophageal and GE Juntion (7575)             Randomized, Placebo-Controlled, double-blind Phase 2 study of mFOLFOX6 chemotherapy plus Ramucirumab Drug Product (IMC-1121B) versus mFOLFOX6 plus placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal junction or Stomach